The content on this site is intended for healthcare professionals only
Dr Carmen Criscitiello speaks at EONS 10, closing the session with a poll of attendees to assess changes in to audiences understanding and awareness of CDK 4/6 therapies.
CDKs were also discussed at an ecancer symposium at ESMO 2016.
Supported by a grant from Pfizer Inc.
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
ESMO 2024: Latest in EGFR mutated NSCLC
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Biomarkers, predictive and prognostic factors of resistance to immunotherapy
GIST tumours and soft tissue sarcomas
Hormonal receptor positive breast cancer adjuvant and metastatic indications
Uncommon genetic aberrations NTRK, RET, NRG
